DailyIQ
Last updated1 minute ago

MCK·McKesson Corporation

$962.13
+6.37 (+0.67%)
Overnight$961.88-0.25 (-0.03%)
High
$969.48
Open
$963.42
Market Cap
112.33B
52W High
$999.00
Low
$954.18
P. Close
$962.13
P/E
24.46
52W Low
$720.01
Fwd P/E
19.02
DailyIQ Est.
$1002.89
Inst. Ownership
40.9%
Short Interest
1.96%
Days to Cover
2.6
Div. Yield
0.35%
Next Ex-Div
~Dec 1
Div. Growth
18+ yrs
Technical Score (1D)
100
BULLISH
News Sentiment
62
BULLISH
On Oct 12, analysts upgraded McKesson after recent acquisitions broadened its portfolio, reflecting confidence that the expanded product mix and distribution network would support continued revenue growth. The re‑rating followed a 170 % rise in McKesson’s shares since 2022, which had drawn attention to the company’s performance. Analysts noted that while the upgrade signals optimism, valuation limits still temper upside potential. The upgrade was reported by the source on Oct 12.
LOW TARGET
$845 -12.2%
1 analysts
MEAN TARGET
$981 +1.9%
14 analysts
HIGH TARGET
$1070 +11.2%
11 analysts
PRICE RANGE
$845.00 - $1070.00
SB / B / H / S / SS
8/11/5/1/1
DAILYIQ EST.
$1002.89 (+4.3%)
Sector
Healthcare
Industry
Medical Distribution
Exchange
NYQ
Country
United States
Symbol
MCK
Description
McKesson Corporation is a global leader in healthcare services, operating through four key segments. Its core business revolves around the distribution of pharmaceuticals, including branded, generic, and specialty drugs, to pharmacies and healthcare providers within the United States and internationally. Beyond distribution, McKesson offers technology and business solutions, supporting community-based oncology practices and providing services to pharmacies. The company's Prescription Technology Solutions segment focuses on connecting various healthcare stakeholders to improve patient access to medication and enhance affordability. Furthermore, McKesson provides medical-surgical supplies and related services to a broad range of healthcare facilities, solidifying its position as a vital partner across the healthcare ecosystem.
Bought (1Y)
0 shares
$0
Sold (1Y)
59,134 shares
$45.4M
Rutledge Napoleon B JRSVP, Controller & CAO
Sell111 shares2026-09-08
Lerman Bradley E-
Sell301 shares2026-08-10
Srinivasan Ramesh (NMN)EVP and Chief Strategy Officer
Award/Grant368 shares2026-08-07
Dunsire Deborah-
Award/Grant277 shares2026-07-22
OZAN KEVIN M-
Award/Grant277 shares2026-07-22
58/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
3.6%
Net Margin
1.2%
Revenue CAGR
8.0%
Current Ratio
0.85x
Debt / Equity
-3.00x
Return on Equity
-219.2%
Earnings Summary
McKesson Corporation operates as a global leader in healthcare services, primarily distributing pharmaceuticals—including branded, generic, and specialty drugs—to pharmacies and healthcare providers worldwide while also offering technology and business solutions that support oncology practices and medical‑surgical supply chains. The company’s operations span four key segments—North American Pharmaceutical, Prescription Technology Solutions, Medical‑Surgical Solutions, and Specialty Pharmacy—positioning it as a central partner across the healthcare ecosystem. In the medical distribution sector, McKesson’s scale and diversified service mix provide a stable revenue base amid evolving payer dynamics and supply‑chain pressures. Recent quarterly results show a mixed trajectory: Q4 2024 EPS of $8.03 beat the $7.99 estimate, but revenue of $95.29 billion fell short of the $95.29 billion estimate; Q1 2025 EPS of $10.12 surpassed the $9.83 estimate, while revenue dipped to $90.82 billion; Q2 2025 EPS of $8.26 exceeded the $8.15 estimate, and revenue rose to $97.83 billion; Q3 2025 EPS of $9.86 beat the $9.05 estimate, with revenue climbing to $103.15 billion. The pattern indicates consistent EPS beats across the last four quarters, though revenue has fluctuated, rising in Q2 and Q3 but falling in Q1 and Q4. Historically, McKesson has maintained a steady YoY revenue growth trajectory, with notable EPS beats in most quarters, while occasional revenue misses suggest sensitivity to market‑wide pricing and cost pressures. Recent news highlights a $5.8 billion acquisition of Option Care Health, expanding the company’s specialty services footprint and potentially boosting higher‑margin revenue streams; the deal also attracted regulatory scrutiny, underscoring governance considerations. Additionally, the announced deployment of artificial intelligence across supply‑chain operations signals a strategic push to improve inventory efficiency and margin compression.

EPS

EstBeatMiss
$7.62$8.77$9.92$11.07$12.22Q1'25Q2'25Q3'25Q4'26Q1'27Q2'27
QtrEstActual+/−
Q2'27$10.75 - -
Q1'27$9.63$9.93+3.1%
Q4'26$11.68$11.69+0.1%
Q3'25$9.05$9.86+8.9%
Q2'25$8.15$8.26+1.4%
Q1'25$9.83$10.12+3.0%

Revenue

EstBeatMiss
$87.8B$94.3B$100.9B$107.4B$114.0BQ1'25Q2'25Q3'25Q4'26Q1'27Q2'27
QtrEstActual+/−
Q2'27$111.0B - -
Q1'27$104.8B$105.4B+0.6%
Q4'26$102.4B$96.3B-5.9%
Q3'25 - $103.2B -
Q2'25 - $97.8B -
Q1'25 - $90.8B -

Market Data

MCK Stock Snapshot

BULLISH100/100
$961.88−$0.25 (0.0%)
Market cap
112.33B
P/E ratio
24.5
Day range
$954.18 – $969.48
News sentiment
62/100 · Bullish
Analyst target
$980.67 (+2.0%)
Consensus
Buy · 26 analysts
52-week range+33.6% off low · -3.7% from high
$720.01$999.00
Price $961.88 DailyIQ Est. $1002.89

MCK's technical picture is constructive, with trend and momentum pointing the same direction. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into MCK?

CHEAP

At today's price, McKesson Corporation needs to grow free cash flow about -0.7% a year for the next 10 years to justify its valuation at a 6.78% cost of capital. Over its actual history it has compounded free cash flow at 8.6% a year, so the market is asking for 9.3 percentage points below its own delivered rate. On that basis MCK looks priced below what its own growth record supports.

Implied FCF growth
-0.7%
Historical FCF CAGR
8.6%
Growth gap
-9.3 pts
Verdict
CHEAP
Discount rate (WACC)
6.78%
Beta
0.36

Behaviour On Record

What MCK's own history says about today's numbers

Realized volatility (21d)
24.8% 60th pct
Below its peak
-5.7%
vs 200-day average
+10.4%
Up days (1y)
53%

McKesson Corporation is currently running 24.8% annualised volatility over the last 21 sessions. Measured against MCK's own 13 years of daily returns rather than a market-wide average, that is the 60th percentile — close to its own typical level, against a typical reading of 22.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

MCK is trading -5.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.7%, and the deepest was -38.8% in 2018. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +10.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 62nd percentile — a somewhat wider gap than its own norm. Over the past year MCK closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, MCK finished the month higher 8 of 13 times, with a median return of +1.4% and an average of +0.0%. Its strongest month historically has been November at +6.3% on average, its weakest August at -2.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: MCK has opened more than 2% away from the prior close in 73 of 3,267 sessions (2.2% of the time), with the largest gaps running +6.6% and -9.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against MCK's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of MCK's sector?

McKesson Corporation sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 12
Sector state
Improving
Sector rotation score
64

Options Market

What is the options market pricing for MCK?

CallsPuts

For McKesson Corporation's nearest expiry (2026-11-20, 37 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 3.1%. The options market is pricing roughly a ±1.0% move by that expiry — a range of about $894.88–$912.87.

Put/call ratio (2026-11-20)
0.00
ATM implied volatility
3.1%
Total open interest
8
Expected move by 2026-11-20
±1.0% ($894.88–$912.87)

Analyst Rating Changes

Are analysts turning bullish or bearish on MCK?

Leerink Partners most recently reiterated its rating on McKesson Corporation to Outperform on Oct 7, 2026 with a price target of $1070 (from $1030). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Leerink Partners — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026Leerink PartnersMaintainedOutperform$1030 → $1070
Sep 14, 2026RBC CapitalReiteratedSector Perform$845
Aug 19, 2026BarclaysMaintainedOverweight$925 → $1000
Aug 19, 2026RBC CapitalInitiatedSector Perform$845
Aug 11, 2026Wells FargoMaintainedEqual-Weight$812 → $933
Aug 6, 2026TD CowenMaintainedBuy$989 → $1006
Aug 6, 2026UBSMaintainedBuy$1050 → $1080
Aug 6, 2026Evercore ISI GroupMaintainedOutperform$860 → $1000
Jul 24, 2026CitigroupMaintainedBuy$945 → $1000
Jul 21, 2026TD CowenMaintainedBuy$1012 → $989
Jun 10, 2026BarclaysMaintainedOverweight$1050 → $925
May 14, 2026CitigroupMaintainedBuy$975 → $945

Peers & ETF holders

MCK peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

62/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
McKesson’s shares had risen 170% since 2022, prompting a new re-rating by analysts. The upgrade was driven by recent acquisitions that broadened the company’s product mix and distribution network. The re-rating signals confidence that the expanded portfolio will support continued revenue growth, though valuation limits still temper upside expectations.
What did this article say?
On October 12, analysts highlighted that McKesson’s share price of $938.84 may be undervalued by roughly 43% despite a recent $1.4 billion infusion. The company’s long‑term track record of strong cash‑flow generation was cited as a key factor supporting the valuation gap. The discounted‑cash‑flow analysis suggested that the current price does not fully reflect the future returns McKesson could deliver to shareholders. The commentary implied that the market has not yet priced in the company’s growth prospects and that a re‑evaluation could lift the stock.
What did this article say?
Baird increased its price target for McKesson to $1,017 from $1,015 in its October 12 report. The adjustment reflects a modest confidence boost in the company’s earnings outlook. The change is unlikely to trigger significant market movement but indicates a slight positive shift in analyst sentiment.
What did this article say?
McKesson Corporation announced a $5.8 billion acquisition of Option Care Health, including debt, to broaden its specialty healthcare services. The deal values Option Care at $32.05 per share, a 37% premium, and partners with Clayton, Dubilier & Rice to take the infusion‑services provider private. McKesson will own 49% of the combined entity and retain the right to buy the remaining stake, positioning the company beyond traditional pharmaceutical distribution into higher‑margin services.
What did this article say?
On Oct 9, MCK became the subject of a shareholder investigation concerning its proposed acquisition of Option Care Health. Securities law firms examined whether the board had secured a fair price and proper process for investors. The probe highlighted potential governance and valuation concerns that could impact the transaction’s viability.
What did this article say?
The article reviews McKesson’s performance over the past ten years, noting the company’s status as a leading North American pharmaceutical distributor. It highlights the firm’s four business segments—North American Pharmaceutical, Prescription Technology Solutions, Medical‑Surgical Solutions, and Specialty Pharmacy—as key drivers of its growth. The piece emphasizes how long‑term investors have benefited from McKesson’s steady expansion and market position, illustrating the potential returns of a decade‑long holding period.
What did this article say?
The article highlighted McKesson Corporation’s potential to benefit from AI integration across its supply chain and logistics operations. It noted that AI could streamline inventory management, reduce waste, and improve forecasting accuracy, thereby enhancing operational efficiency. Analysts projected that these technological upgrades would support higher margins and strengthen McKesson’s competitive position in the healthcare services sector. The piece emphasized that the company’s current initiatives are aligned with broader industry trends toward digital transformation.
What did this article say?
McKesson (MCK) achieved a year‑to‑date return that outpaces many peers in the medical sector, according to Zacks analysis. The company holds a Zacks Rank of #2 (Buy), reflecting a 1% lift in its full‑year earnings estimate over the past three months. Analysts view the upward revision as evidence of improving earnings outlook and positive sentiment. The firm’s performance aligns with a sector rank of #11, suggesting it is a strong performer within a broad group of 916 medical stocks. Overall, the data indicate a solid, positive trajectory for MCK.
What did this article say?
On October 8, analysts across 16 brokerage firms issued a consensus rating for McKesson (MCK) that leaned toward a strong buy, with 75% of the recommendations classified as such. The average brokerage recommendation (ABR) of 1.50, positioned between strong buy and buy, reflected a bullish stance on the company’s prospects. The piece underscored the limited predictive power of such ratings, suggesting caution despite the positive sentiment. Overall, the coverage presented a moderate positive outlook for MCK based on analyst consensus.

Technical Analysis

Real-time indicators across multiple timeframes

100
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $36.80B combined position · 10 adding, 15 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy12,104,71910.36%$9.93B2026-01-29
BlackRock, Inc.▼ Sell10,795,0549.24%$8.16B2026-08-07
Morgan Stanley▲ Buy5,306,1424.54%$4.01B2026-08-13
Geode Capital Management, LLC▼ Sell2,822,1552.42%$2.12B2026-08-12
FMR LLC (Fidelity)▼ Sell2,130,2881.82%$1.61B2026-08-13
AllianceBernstein L.P.▼ Sell1,686,9931.44%$1.46B2026-08-14
JPMorgan Chase & Co▼ Sell1,748,8601.50%$1.31B2026-08-12
Norges Bank▼ Sell1,529,0561.31%$1.16B2026-08-12
Northern Trust Corp▼ Sell1,442,3401.24%$1.09B2026-08-13
Bank of America Corp▼ Sell1,321,9911.13%$998.90M2026-08-14
Goldman Sachs Group Inc▲ Buy1,321,1291.13%$998.25M2026-08-14
Invesco Ltd.▼ Sell981,1730.84%$741.37M2026-08-14
AQR Capital Management LLC▼ Sell878,7270.75%$660.95M2026-08-14
Janus Henderson Group plc▼ Sell628,9450.54%$544.23M2026-05-18
D. E. Shaw & Co., Inc.▲ Buy483,8430.41%$365.59M2026-08-14
Citadel Advisors LLC▲ Buy460,4090.39%$347.89M2026-09-02
Wells Fargo & Company▼ Sell404,2340.35%$305.44M2026-08-14
Renaissance Technologies LLC▲ Buy361,0860.31%$272.84M2026-08-13
Squarepoint Ops LLC▲ Buy190,2800.16%$143.78M2026-08-14
Man Group plc▼ Sell170,9450.15%$129.17M2026-08-14
Citigroup Inc▲ Buy156,7230.13%$118.42M2026-08-03
Prudential Financial Inc▼ Sell141,9780.12%$107.28M2026-08-12
Neuberger Berman Group LLC▼ Sell120,6340.10%$91.15M2026-08-13
Millennium Management LLC▲ Buy101,1330.09%$76.42M2026-08-14
Gotham Asset Management, LLC▲ Buy76,6770.07%$57.94M2026-08-14
Q2 2026 flow:4.30M sh bought ($3.25B)5.60M sh sold ($4.28B)net -1.30M sh (−$1.03B)
Congressional Trading Activity
25 disclosed trades · ~$249.0K est. traded value · 15 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Rick LarsenHouseWA02▲ Buy$1K - $15K2026-07-082026-07-12
Jonathan JacksonHouseIL01▼ Sell$1K - $15K2026-06-152026-07-15
Elizabeth FletcherHouseTX07▼ Sell$1K - $15K2026-04-082026-05-01
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-12-192026-01-12
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-12-022026-01-16
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-10-102025-11-22
Jonathan JacksonHouseIL01▼ Sell$1K - $15K2025-10-082025-11-10
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Valerie HoyleHouseOR04▲ Buy$1K - $15K2025-09-102025-10-10
Ritchie John TorresHouseNY15▼ Sell$1K - $15K2025-07-112025-08-20
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-04-292025-05-06
Jonathan JacksonHouseIL01▲ Buy$1K - $15K2025-04-232025-08-25
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-092025-05-14
Jonathan JacksonHouseIL01▲ Buy$1K - $15K2025-03-242025-08-25
Jonathan JacksonHouseIL01▲ Buy$1K - $15K2025-03-042025-04-08
Jonathan JacksonHouseIL01▲ Buy$1K - $15K2025-03-032025-08-25
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-01-242025-02-11
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-01-152025-02-10
Ritchie John TorresHouseNY15▲ Buy$1K - $15K2025-01-072026-07-08
Julia LetlowHouseLA05▲ Buy$1K - $15K2024-12-182026-01-13
Sheldon WhitehouseSenateRI▼ Sell$15K - $50K2017-09-202017-10-12
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2017-02-232017-03-15